Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits

Key Result

Cardiorenometabolic medicine integrates pharmacologic, behavioral, and metabolic dimensions to optimize patient outcomes using novel pharmaceuticals with dual or triple benefits.

Key Points

• The research aims to propose a new subspecialty in medicine that focuses on integrating various treatment dimensions for better health outcomes.
• Proposing a holistic and risk-adapted approach.
• Integrating pharmacologic and behavioral strategies.
• Focusing on metabolic dimensions to optimize care.
• Enhanced patient outcomes through integrated care.
• Potential for transformation in cardiometabolic care.
• Emphasis on dual or triple benefits of new pharmaceuticals.